Resistant to refractory hypertension: Angiotensin receptor blocker/neprilysin inhibitor to the rescue
Medicine India · 2023
DOI: 10.25259/medindia_17_2022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medicine India, 2023. Verfasst von Basil Nwaneri Okeahialam. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
Hypertension in African starts early and runs a severe course; with appalling morbi-mortality statistics. When resistant to treatment, again a phenotype more common in the African, outcome is poorer. Search for effective management has continued, ranging from novel pharmacological agents to devise therapy. The latter is invasive and beyond the reach of many needing it. Angiotensin receptor blocker/Neprilysin inhibitors are relatively new in our environment and effective in hypertensives with high salt intake and sensitivity. Since this is the situation with majority of African hypertensives, it was given to a patient with diabetes and treatment resistant hypertension of the refractory phenotype. The outcome was satisfactory hence this case report.
Zitieren
APA
Okeahialam, B. N. (2023). Resistant to refractory hypertension: Angiotensin receptor blocker/neprilysin inhibitor to the rescue. Medicine India. https://doi.org/10.25259/medindia_17_2022
Vancouver
Okeahialam BN. Resistant to refractory hypertension: Angiotensin receptor blocker/neprilysin inhibitor to the rescue. Medicine India. 2023. doi:10.25259/medindia_17_2022
BibTeX
@article{Okeahialam2023,
author = {Okeahialam, Basil Nwaneri},
title = {Resistant to refractory hypertension: Angiotensin receptor blocker/neprilysin inhibitor to the rescue},
journal = {Medicine India},
year = {2023},
doi = {10.25259/medindia_17_2022}
}
EUVIMED